Therapy and Trigger – an Unusual Case of Optic Neuritis

Introduction

Tumor necrosis factor alpha (TNF-α) inhibitors are widely used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohnʼs disease and psoriatic arthritis. Although generally effective and well tolerated, these agents have been implicated in rare but serious central nervous system (CNS) complications, including demyelinating events. Optic neuritis is a well-recognized manifestation of CNS demyelination, typically occurring in association with multiple sclerosis (MS). Its occurrence in patients treated with TNF-α inhibitors has been described but remains insufficiently acknowledged. We report the case of a young female patient who developed unilateral optic neuritis while receiving long- term golimumab therapy, for which a possible association is considered.

Publikationsverlauf

Eingereicht: 29. Oktober 2025

Angenommen: 05. Januar 2026

Artikel online veröffentlicht:
17. Februar 2026

• References

• 1 Jacobs S. Atypical Optic Neuritis Induced by Golimumab Treatment for Psoriasis Arthritis. Neurology Advisor 2022. Accessed 05.10.2025 at: https://www.neurologyadvisor.com/news/atypical-optical-neuritis-golimumab-treatment-psoriasis-arthritis-aan-2022/
• 2 De Frutos-Lezaun M, Garcia-Sanchez I, Vicente-Villalba C. et al. Bilateral retrobulbar optic neuropathy associated with golimumab. Clin Neuropharmacol 2017; 40: 149-151
• 3 Gharib MH, AlKahlout MA, Garcia Canibano B. et al. Demyelinating neurological adverse events following the use of anti-TNF-α agents: a double-edged sword. Case Rep Neurol Med 2022; 2022: 3784938
• 4 Gogulescu A, Blidisel A, Soica C. et al. Neurological side effects of TNF-α inhibitors revisited: a review of case reports. Medicina (Kaunas) 2024; 60: 1409
• 5 Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNF-α inhibitor exposure: a retrospective cohort study. J Neuroimmunol 2021; 356: 577587
• 6 Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017; 17: 36
• 7 Li L, Aviña-Zubieta JA, Bernstein CN. et al. Risk of multiple sclerosis among users of antitumor necrosis factor α in four Canadian provinces: a population-based study. Neurology 2023; 100: e558-e567
• 8 Simsek I, Erdem H, Pay S. et al. Optic neuritis occurring with anti-tumour necrosis factor α therapy. Ann Rheum Dis 2007; 66: 1255-1258
• 9 Winthrop KL, Chen L, Fraunfelder FW. et al. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic therapy (SABER) study. Am J Ophthalmol 2013; 155: 183-189.e1